Page last updated: 2024-11-04

cyproheptadine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyproheptadine is an antihistamine and antiserotonin drug that is used to treat a variety of conditions, including allergies, itching, and migraines. It is also sometimes used as an appetite stimulant. Cyproheptadine is a synthetic compound that was first synthesized in the 1950s. The drug is available in various forms, including tablets, capsules, and syrup. Cyproheptadine works by blocking the effects of histamine and serotonin, which are chemicals that are released in the body in response to allergic reactions and other stimuli. By blocking these chemicals, cyproheptadine can help to relieve the symptoms of allergies, itching, and migraines. Cyproheptadine is also effective at stimulating appetite because it blocks the effects of serotonin, which is a neurotransmitter that plays a role in regulating appetite. Cyproheptadine is generally well-tolerated, but it can cause side effects, such as drowsiness, dry mouth, and dizziness. The drug is also not recommended for use in children or pregnant women. It is important to note that this information is for educational purposes only and should not be considered medical advice. Always talk to your doctor before starting any new medication.'

Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2913
CHEMBL ID516
CHEBI ID4046
SCHEMBL ID4021
MeSH IDM0005519

Synonyms (131)

Synonym
BIDD:GT0324
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
gtpl277
cyproheptidine
1-methyl-4-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}piperidine
4-(5h-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
BIOMOL-NT_000131
eiproheptadine
piperidine, 4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-
lopac-c-6022
tocris-0996
NCGC00015252-01
NCGC00024293-02
NCGC00015252-02
cas-969-33-5
PDSP2_001213
ciprovit (tn)
cyproheptadine (inn)
D07765
BSPBIO_000086
BPBIO1_000155
BPBIO1_000096
PDSP1_001229
OPREA1_498140
LOPAC0_000246
PRESTWICK3_000103
dronactin
hsdb 3048
4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
cyproheptadine [inn:ban]
cyproheptadinum [inn-latin]
mk 141
ccris 5232
einecs 204-928-9
ciproheptadina [inn-spanish]
piperidine, 4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-
brn 1685976
4-(dibenzo[[?],[?]][7]annulen-11-ylidene)-1-methyl-piperidine
periactin
4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
129-03-3
cyproheptadine
C06935
4-dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine
1-methyl-4-(5h-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene
DB00434
4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
periactinol
NCGC00024293-05
SPBIO_002025
PRESTWICK1_000103
PRESTWICK0_000103
PRESTWICK2_000103
NCGC00024293-04
NCGC00015252-03
HMS2090P20
NCGC00015252-09
L001016
ciprovit
CHEMBL516 ,
cyproheptadinum
ciproheptadina
CHEBI:4046 ,
STK802098
bdbm50017721
4-(5h-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine4-(5h-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
NCGC00015252-08
AKOS004119847
BBL010977
dtxcid702872
cas-129-03-3
dtxsid8022872 ,
tox21_110112
cyproheptadiene
cypoheptadine
CCG-204341
NCGC00015252-06
NCGC00015252-04
NCGC00015252-07
NCGC00015252-05
NCGC00015252-10
5-20-08-00500 (beilstein handbook reference)
unii-2yhb6175do
2yhb6175do ,
FT-0631755
NCGC00015252-13
cyproheptadine [mi]
cyproheptadine [hsdb]
cyproheptadine [who-dd]
cyproheptadine [vandf]
cyproheptadine [inn]
DL-136
SCHEMBL4021
tox21_110112_1
NCGC00015252-12
reactin
peritol (salt/mix)
1-methyl-4-(5h-dibenzo[a,d]cycloheptenylidene)piperidine
1-methyl-4-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene}piperidine
4-(dibenzo[1,2-a:2',1'-d][7]annulen-11-ylidene)-1-methyl-piperidine
SBI-0050234.P002
BRD-K28143534-001-03-0
Q417884
1-methyl-4-{tricyclo[9.4.0.0(3),?]pentadeca-1(11),3,5,7,9,12,14-heptaen-2-ylidene}piperidine
VS-02784
BRD-K28143534-003-14-3
SDCCGSBI-0050234.P003
NCGC00015252-26
1-methyl-4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidinehydrochloride
A915360
1-methyl-4-(2-tricyclo[9.4.0.0^{3,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine
EN300-18552723
1-methyl-4-{tricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-2-ylidene}piperidine
HY-B1622
CS-0013555
ciproeptadina
cyproheptadin
r06ax02
4-(5h-dibenzo(a,d)(7)annulen-5-ylidene)-1-methylpiperidine
5-(1-methylpiperidylidene-4)-5h-dibenzo
4-(5h-dibenzo
1-methyl-4-(5-dibenzo
ciproheptadina (inn-spanish)
cyproheptadinum (inn-latin)
1-methyl-4-(5h-dibenzo
4-dibenzo(a,d)cyclohepten-5-ylidene-1-methyl-piperidine

Research Excerpts

Overview

Cyproheptadine HCl (CyproH) is an appetite-stimulating drug. While it was prescribed for a patient with growth hormone insensitivity syndrome (GHIS) for increasing appetite, his height growth was surprisingly increased.

ExcerptReferenceRelevance
"Cyproheptadine is a safe treatment option in patients with poor appetite."( Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.
Cho, B; Cho, KH; Cho, YG; Kim, SY; Lee, JW; Park, YG; Yun, JM, 2021
)
1.63
"Cyproheptadine HCl (CyproH) is an appetite-stimulating drug and while it was prescribed for a patient with growth hormone insensitivity syndrome (GHIS) for increasing appetite, his height growth was surprisingly increased. "( A novel treatment for height growth in patients with growth hormone insensitivity syndrome by cyproheptadine hydrochloride.
Nourbakhsh, M; Razzaghy-Azar, M, 2018
)
2.14
"Cyproheptadine is a serotonin and histamine antagonist that has been suggested as a treatment for serotonin syndrome in case reports."( An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System.
Cantrell, LF; Kearney, T; Nguyen, H; Pan, A; Smollin, C, 2019
)
2.23
"Cyproheptadine (Cph) is an antiserotoninergic and antihistaminergic agent with alpha-blocking activity and central sedative effect. "( Antisecretory effect of prescribed appetite stimulator drug cyproheptadine in rat intestine.
Eto, B; Limas-Nzouzi, N; Mamadou, G; Meddah, B; Miantezila, J; Soudy, ID, 2014
)
2.09
"Cyproheptadine is a medication with antihistaminergic, antiserotonergic and anticholinergic effects, thought to increase gastric accommodation."( A retrospective review of cyproheptadine for feeding intolerance in children less than three years of age: effects and side effects.
Butler, DR; Kaul, A; Meinzen-Derr, J; Merhar, SL; Mukkada, VA; Pentiuk, SP, 2016
)
1.46
"Cyproheptadine (Periactin) is a first-generation antihistamine available in over-the-counter cold medications and is used to treat allergic-type symptoms. "( A fatality due to cyproheptadine and citalopram.
Hargrove, V; Molina, DK, 2009
)
2.13
"Cyproheptadine (CPH) is a histamine- and serotonin-receptor antagonist, and its effects are observed recently in the modulation of multiple intracellular signals. "( Cyproheptadine enhances the I(K) of mouse cortical neurons through sigma-1 receptor-mediated intracellular signal pathway.
Gao, XF; He, YL; Hu, CL; Mei, YA; Yao, JJ; Zhang, CL, 2012
)
3.26
"Cyproheptadine is a cheap and safe drug that does not have significant interactions with antiretroviral drugs. "( Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
Dabaghzadeh, F; Dashti-Khavidaki, S; Ghaeli, P; Khalili, H, 2012
)
2.14
"Cyproheptadine is a piperidine antihistamine that increases appetite through its antiserotonergic effect on 5-HT2 receptors in the brain."( Effect of cyproheptadine on serum leptin levels.
Calka, O; Dülger, H; Erkoç, R; Metin, A,
)
1.26
"Cyproheptadine is a cheap, widely available anti-allergy drug with a broad receptor binding profile which resembles that of clozapine. "( Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats.
Cole, JC; Cooper, GD; Goudie, AJ; Sumnall, HR, 2007
)
3.23
"Cyproheptadine is a potent antagonist of serotonin and has been used successfully in some patients with Cushing's disease, although, generally, in women without radiological evidence of pituitary tumors."( Cyproheptadine-induced remission of Cushing's disease due to pituitary basophil adenoma.
Bellido, C; Jaimez, L; Jimenez-Alonso, J; Jiménez-Perepérez, JA; Munoz-Avila, J; Pérez-Jimenez, F, 1982
)
2.43
"Cyproheptadine is a serotonergic antagonist that has been suggested for the treatment of schizophrenia."( The effects of cyproheptadine on vacuous jaw movements in rats: a comparison with haloperidol and clozapine.
Harrington, A; Kaczmarek, HJ; Steinpreis, RE, 1996
)
1.37
"Cyproheptadine is a drug that shows high affinity for type 2 (5-HT2) receptors. "( Synthesis, affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues.
Cadavid, MI; Calleja, JM; Dominguez, R; Honrubia, MA; Loza, MI; Lozoya, E; Maayani, S; Manaut, F; Rodriguez, J; Sanz, F; Seijas, JA; Villaverde, MC, 1997
)
1.95
"Cyproheptadine is an antihistamine and serotonin antagonist given to children for allergies, migraine headaches, and growth problems. "( Case study: cyproheptadine and aggression in a five-year-old boy.
Strayhorn, JM, 1998
)
2.12
"Cyproheptadine is a relatively safe compound and may be of therapeutic benefit in treating negative symptoms of schizophrenia in combination with typical neuroleptics. "( Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study.
Akhondzadeh, S; Amini-Nooshabadi, H; Davari-Ashtiani, R; Mohammadi, MR, 1999
)
3.19
"Cyproheptadine is a drug with direct antimuscarinic, antihistaminic (H1) and antiseronergic (5HT2) effects. "( [Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine].
Alcaina Prosper, T; De Lucas Taracena, MT; Huélamo Ortega, MJ,
)
1.84
"Cyproheptadine is an agent with considerable side effects, and it should be prescribed to children only after very careful deliberation."( [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)].
Krienke, EG; von Mühlendahl, KE, 1978
)
1.35
"Cyproheptadine would appear to be a useful therapeutic tool for the management of diarrhea associated with the malignant carcinoid syndrome."( A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome.
Kvols, LK; Moertel, CG; Rubin, J, 1991
)
1.39
"Cyproheptadine is an antagonist of S1 serotoninergic and H1 histaminergic receptors, with a well known cardiovascular activity, mainly vasodilation and a negative chronotropic effect. "( [Effects of cyproheptadine on the electrophysiological characteristics of the sinus node, ventricular myocytes and papillary muscles of the guinea pig heart].
Almanza, J; Santillán, A; Valenzuela, F,
)
1.95
"Cyproheptadine (CH) is a serotonin antagonist that increases food intake and body weight. "( Reduction of negative alliesthesia for sweet gustatory stimuli by cyproheptadine, a serotonin antagonist.
Brondel, L; Fantino, M; Lebec, O; Swiergiel, AH, 1990
)
1.96
"Cyproheptadine is an antihistamine with antiserotoninergic and anticholinergic properties. "( Choreoathetosis induced by cyproheptadine.
Ashton, AK; Samie, MR, 1989
)
2.02

Effects

Cyproheptadine has been reported to effect remissions in up to 50% of patients with Cushing's disease presumably at a hypothalamic level. The drug has been shown in medical samples to stimulate weight gain.

ExcerptReferenceRelevance
"Cyproheptadine has a unique pharmacologic portfolio that speaks to the idea of a pluripotent molecule beyond an antiallergic agent which can expand its therapeutic potential to address a multitude of psychiatric indications. "( Cyproheptadine
Badr, B; Naguy, A, 2022
)
3.61
"Cyproheptadine has a unique pharmacologic portfolio that speaks to the idea of a pluripotent molecule beyond an antiallergic agent which can expand its therapeutic potential to address a multitude of psychiatric indications. "( Cyproheptadine
Badr, B; Naguy, A, 2022
)
3.61
"Cyproheptadine has been shown to produce dose-dependent inhibition of haem polymerization activity both in vitro and in vivo."( Haem polymerase as a novel target of antimalarial action of cyproheptadine.
Agrawal, R; Dutta, GP; Jain, SK; Shukla, OP; Tekwani, BL; Tripathi, R, 2002
)
1.28
"Cyproheptadine has been shown in medical samples to stimulate weight gain."( A chart review of cyproheptadine for stimulant-induced weight loss.
Daviss, WB; Scott, J, 2004
)
1.38
"Cyproheptadine has recently been reported to blunt the furosemide-induced rise in PRA in normal subjects and to acutely lower plasma aldosterone levels in patients with hyperaldosteronism due to bilateral adrenal hyperplasia; both actions have tentatively been ascribed to the antiserotoninergic action of the drug. "( Cyproheptadine and mineralocorticoid effector mechanisms.
Adam, WR; Armanini, D; Funder, JW; Goland, GJ, 1983
)
3.15
"Cyproheptadine (CY) has been used therapeutically as an appetite stimulant at a dose which appears to have antiserotoninergic activity. "( Effect of cyproheptadine hydrochloride on ingestive behaviors.
Dellia-Sfikaki, A; Konstandi, M; Varonos, D, 1996
)
2.14
"Cyproheptadine has especially high affinity for the H2-receptor."( Defining the histamine H2-receptor in brain: the interaction with LSD.
Green, JP; Maayani, S; Weinstein, H, 1978
)
0.98
"Cyproheptadine has been used to counteract these side effects."( Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa.
Goldbloom, DS; Kennedy, SH, 1991
)
1.27
"Cyproheptadine has been reported to effect remissions in up to 50% of patients with Cushing's disease presumably at a hypothalamic level. "( Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation.
Jackson, IM; Nowakowski, KJ; Tucci, JR, 1989
)
3.16

Actions

Cyproheptadine was found to inhibit the Ca2+ uptake of sarcoplasmic reticulum with an IC50 of 1.94 x 10(-4) mol/L. Cyprohepticadine tended to increase (P < .10) LH pulsatility on d 5 and 14, but MEL had no effect.

ExcerptReferenceRelevance
"Cyproheptadine was found to inhibit the Ca2+ uptake of sarcoplasmic reticulum with an IC50 of 1.94 x 10(-4) mol/L."( [Effect of cyproheptadine on Ca2+,Mg(2+)-ATPase activities and 45Ca2+ uptake function in canine myocardial sarcoplasmic reticulum].
Xin, HB; Zhang, BH, 1993
)
1.4
"Cyproheptadine tended to increase (P < .10) LH pulsatility on d 5 and 14, but MEL had no effect (P > .20)."( Luteinizing hormone and ovarian response of early postpartum Debouillet ewes treated with cyproheptadine and(or) melatonin.
Hallford, DM; Kridli, RT, 1997
)
1.24
"for cyproheptadine. Using an increase in food consumption of 20% or more as the criterion of a positive response, the dose effective in 50% of the animals was 0.35 mg/kg p.o."( Appetite stimulant activity of 3-carboxy-10,11-dihydrocyproheptadine.
Clineschmidt, BV; Hanson, HM; Lotti, VJ; McGuffin, JC; Scriabine, A; Stone, CA, 1976
)
0.98
"The cyproheptadine-induced increase in energy intake was statistically significant in one of the subjects, who was at his desirable weight level at the outset."( Ingestive behavior and composition of weight change during cyproheptadine administration.
Hashim, SA; Saleh, JW; van Itallie, TB; Yang, MU, 1979
)
0.98

Treatment

Treatment with cyproheptadine, a 5HT antagonist, did not delay parturition. Treatment again induced hypocorticism necessitating corticosteroid substitution therapy.

ExcerptReferenceRelevance
"Cyproheptadine is a safe treatment option in patients with poor appetite."( Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.
Cho, B; Cho, KH; Cho, YG; Kim, SY; Lee, JW; Park, YG; Yun, JM, 2021
)
1.63
"Cyproheptadine pretreatment inhibited ether-induced ACTH hypersecretion in adrenalectomized animals."( Lack of correlation between hypothalamic serotonin and the ether-induced ACTH secretion in adrenalectomized rats.
Fekete, MI; Kanyicska, B; Karteszi, M; Kiss, JZ; Palkovits, M; Stark, E, 1981
)
0.98
"Cyproheptadine pretreatment did not alter plasma levels of fenfluramine."( Serotonergic stimulation of adrenocorticotropin secretion in man.
Lewis, DA; Sherman, BM, 1984
)
0.99
"Cyproheptadine pretreatment blocked or largely inhibited the cutaneous vasoconstriction produced by serotonin only in doses which also inhibited norepinephrine and vasopressin cutaneous vasoconstriction."( Evidence that serotonin receptors mediate the cutaneous vasoconstriction produced by 5-hydroxytryptamine in canine forelimbs.
Adamski, SW; Dobbins, DE; Grega, GJ; Lokhandwala, MF, 1983
)
0.99
"Cyproheptadine pretreatment resulted in a substantial suppression of the GH response to glucagon."( The effect of TRH, cyproheptadine and pimozide on the growth hormone response to intramuscular glucagon.
Hainer, V; Krejcik, L; Malec, B; Urbánek, J, 1981
)
1.31
"In cyproheptadine-treated animals the incidence and severity of clinical manifestations and pathologic alterations were reduced, and mortality was marked decreased."( Amelioration of decompression sickness in mice by pretreatment with cyproheptadine.
Chryssanthou, C; Graber, B; Rubin, L, 1980
)
1.01
"Cyproheptadine treatment was beneficial in more than two thirds of treated horses."( Owner survey of headshaking in horses.
Bell, SA; Madigan, JE, 2001
)
1.03
"Cyproheptadine treatment resulted in a marked lowering of plasma ACTH concentrations (221-320 pg/ml)."( Cortisol and androgen secretion in a case of Nelson's syndrome with paratesticular tumors: response to cyproheptadine therapy.
Bardin, CW; Krieger, DT; Samojlik, E, 1978
)
1.19
"Cyproheptadine pretreatment also prevented the hyperinsulinemia and hypoglucagonemia resulting from glucose loading."( Paradoxical short-term effects of cyproheptadine on insulin and glucagon release in the rat.
Bryce, GF; Jacoby, JH, 1979
)
1.26
"Cyproheptadine pretreatment was associated with erratic increases or decreases in the hGH response to apomorphine, but did not alter PRL levels or apomorphine-induced PRL suppression."( Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
Angrist, B; Branchey, L; Gershon, S; Halpern, F; Oleshansky, M; Paquin, J; Rotrosen, J; Sachar, EJ, 1979
)
0.98
"Cyproheptadine pretreatment failed to depress the quipazine (serotonin agonist)-induced PRL rise."( Cyproheptadine stimulated prolactin release in the young turkey (Meleagris gallopavo).
el Halawani, ME; Fehrer, SC; Silsby, JL, 1985
)
2.43
"Cyproheptadine pre-treatment did not alter plasma levels of fenfluramine."( Serotonergic regulation of prolactin and growth hormone secretion in man.
Lewis, DA; Sherman, BM, 1985
)
0.99
"Pre-treatment with cyproheptadine also resulted in a decrease of other toxic symptoms associated with Boophone disticha."( Pre-treatment of BALB/c mice with a centrally acting serotonin antagonist (cyproheptadine) reduces mortality from Boophone disticha poisoning.
Gadaga, LL; Mutseura, M; Tagwireyi, D, 2013
)
0.94
"Treatment with cyproheptadine, a 5HT antagonist, did not delay parturition."( THE 5-HYDROXYTRYPTAMINE CONTENT OF THE PLACENTA AND FOETUS DURING PREGNANCY IN MICE.
ROBSON, JM; SENIOR, JB, 1964
)
0.58
"Treatment with cyproheptadine was attempted."( Headshaking in a 10-year-old Thoroughbred mare.
Bell, AJ, 2004
)
0.66
"Treatment with cyproheptadine again induced hypocorticism necessitating corticosteroid substitution therapy."( Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease.
Croughs, RJ; Koppeschaar, HP; Schwarz, F; Thijssen, JH, 1983
)
0.92
"Dogs treated with cyproheptadine both prior to and after induction of endotoxin shock were compared with the standard endotoxin shock model."( Effect of cyproheptadine on endotoxin-induced pulmonary platelet trapping.
Almqvist, P; Kuenzig, M; Schwartz, SI; Skudder, P, 1984
)
0.99
"Treatment with cyproheptadine was continued till six weeks after delivery by which time all the features of Cushing's syndrome had disappeared."( Two pregnancies in a woman with Cushing's syndrome treated with cyproheptadine. Case report.
Hartwig, W; Kasperlik-Załuska, A; Lozińska, D; Marianowski, L; Migdalska, B; Stopińska-Głuszak, U; Wilczyńska, J, 1980
)
0.84
"pretreatment with cyproheptadine attenuated the inhibition of the tail-flick response induced by i.t."( Effects of intrathecally injected histamine receptor antagonists on the antinociception induced by morphine, beta-endorphin, and U50, 488H administered intrathecally in the mouse.
Choi, YS; Kim, YH; Song, DK; Suh, HW, 1996
)
0.62
"Treatment with cyproheptadine produced improvement of symptoms in 76% of cases."( Characterisation of headshaking syndrome--31 cases.
Bell, SA; Madigan, JE, 1998
)
0.64
"pretreatment with cyproheptadine or thioperamide dose-dependently attenuated the inhibition of the tail-flick response induced by i.c.v."( Effects of histamine receptor antagonists injected intrathecally on antinociception induced by opioids administered intracerebroventricularly in the mouse.
Chung, KM; Huh, SO; Kim, YH; Song, DK; Suh, HW, 1999
)
0.63
"Treatment with cyproheptadine is not thought to abbreviate the illness, but provides symptomatic relief while symptoms persist."( Serotonin syndrome: early management with cyproheptadine.
McDaniel, WW,
)
0.74
"Treatment with cyproheptadine, indomethacin, or theophylline had no effect, but treatment with dexamethasone significantly reduced PS to near normal levels."( Vascular response to fractionated irradiation in the rat lung.
Evans, ML; Graham, MM; Peterson, LM; Thomas, KL, 1992
)
0.62
"Pretreatment with cyproheptadine significantly inhibited the fall in FEV1.0 120 minutes after ethanol challenge (p less than 0.05)."( [The inhibitory effects of anti-asthmatic agents on ethanol-induced bronchoconstriction in Japanese asthmatic patients].
Asai, S; Hara, K; Inuyama, M; Kiya, T; Miura, N; Sakamoto, Y; Shimoda, T; Tomonaga, H; Watanabe, T, 1992
)
0.61
"Pretreatment with cyproheptadine (2.5 mg/kg, iv), a dual serotonin/histamine antagonist, or ketanserin (3 mg/kg, iv), a selective serotonin antagonist, prevented the GH-RP-6-induced hypotension and lethality."( Hypotension induced by growth-hormone-releasing peptide is mediated by mast cell serotonin release in the rat.
Gabel, RA; Macia, RA; Matthews, WD; Reginato, MJ, 1990
)
0.6
"Pretreatment with cyproheptadine (5 mg/kg), an inhibitor of both histamine and serotonin, significantly suppressed pleural fluid accumulation and the exudation rate at 0.5 hr."( Involvement of platelet-activating factor in zymosan-induced rat pleurisy.
Hayashi, M; Imai, Y; Oh-ishi, S, 1991
)
0.6
"Pretreatment with cyproheptadine, a 5-HT2 receptor antagonist, prevented the BBB increase and the regional blood flow was near normal values."( Changes in blood-brain barrier and cerebral blood flow following elevation of circulating serotonin level in anesthetized rats.
Dey, PK; Olsson, Y; Sharma, HS, 1990
)
0.6
"Pretreatment with cyproheptadine (1.5 and 3 mg/kg), methysergide (5 and 10 mg/kg) and (-)-propranolol (2.5 and 5 mg/kg) significantly decreased the number of head twitches induced by ergometrine."( Head-twitch response induced by ergometrine in mice: behavioural evidence for direct stimulation of central 5-hydroxytryptamine receptors by ergometrine.
Balsara, JJ; Bapat, TR; Chandorkar, AG; Gada, VP; Nandal, NV, 1986
)
0.59
"Pretreatment with cyproheptadine and vinblastine, however, prevented only the increased permeability of the blood-brain barrier; the plasma and level of 5-HT in brain continued to remain high."( Probable involvement of 5-hydroxytryptamine in increased permeability of blood-brain barrier under heat stress in young rats.
Dey, PK; Sharma, HS, 1986
)
0.59
"Treatment with cyproheptadine caused a documented response in the patient's debilitating diarrhoea and also produced symptomatic improvement in her muscular power."( Carcinoid myopathy and treatment with cyproheptadine (Periactin).
Berry, EM; Maunder, C; Wilson, M, 1974
)
0.86

Toxicity

Cyproheptadine prevention of the neuropsychiatric adverse effects of an antiretroviral regimen including efavirenz has been evaluated. In other trials, prior treatment with diethylcarbamazine (DEC) was found to potentiate the lethality of FN.

ExcerptReferenceRelevance
" In other trials, prior treatment with diethylcarbamazine (DEC) was found to potentiate the lethality of FN, while cyproheptadine (CHP) pretreatment attenuated FN's toxic effects."( A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat.
Hunsinger, RN; Wright, D,
)
0.34
" Loratadine appears to be a simple, effective and safe therapy for seasonal allergic rhinitis."( Efficacy and safety of loratadine suspension in the treatment of children with allergic rhinitis.
Andreoli, A; Boner, AL; Marchesi, E; Miglioranzi, P; Richelli, C, 1989
)
0.28
" Neither terfenadine nor loratadine, another nonsedating antihistamine, potentiated the adverse effects of alcohol on driving performance."( Antihistamines and driving safety.
O'Hanlon, JF, 1988
)
0.27
" Loratadine was found to be both safe and efficacious."( Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis.
Bergner, A; Connell, JT; Dockhorn, RJ; Falliers, CJ; Grabiec, SV; Shellenberger, MK; Weiler, JM, 1987
)
0.27
" All treatments were well tolerated and no serious adverse events were recorded."( A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Dumur, JP; Izquierdo, I; Pérez, I; Saint-Martin, F, 2004
)
0.32
"The present results suggest that rupatadine 10 mg a day may be a valuable and safe alternative for the symptomatic treatment of seasonal allergic rhinitis."( A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Dumur, JP; Izquierdo, I; Pérez, I; Saint-Martin, F, 2004
)
0.32
" Tolerability was based on the recording of adverse events (AEs), physical examination, electrocardiograms, and laboratory screen controls at baseline and the final study visit."( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008
)
0.35
"Rupatadine (Rupafin), a novel antihistamine approved recently in Europe for the treatment of allergic rhinitis (AR) and chronic idiopathic urticaria in patients aged>or=12 years, has been shown to be highly efficacious, and as safe and well tolerated as other commonly employed antihistamines in the treatment of allergic disease."( Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Antépara, I; Borja, J; Castillo, JA; de la Torre, F; del Cuvillo, A; Donado, E; Izquierdo, I; Molà, O; Rivas, P; Valero, A, 2009
)
0.35
" Safety was assessed by means of adverse events (AEs) reported by patients or detected by investigators, scheduled centralized ECG with special attention to Bazzet corrected QT interval (QTcB) and standard laboratory investigations."( Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Antépara, I; Borja, J; Castillo, JA; de la Torre, F; del Cuvillo, A; Donado, E; Izquierdo, I; Molà, O; Rivas, P; Valero, A, 2009
)
0.35
" However, the neural mechanism by which extracellular 5-HT is elevated to a toxic level for the syndrome remains to be determined."( Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.
Huang, X; Krishnamoorthy, S; Ma, Z; Tao, R; Vukovich, NP; Zhang, G, 2009
)
0.35
" Adverse events occurred in 19."( Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis.
Antila, M; Campos, RA; Castro, FM; Chavarria, ML; de Mello Junior, JF; de Mello, JF; Di Gesu, G; Guimarães, RE; Mion, Ode G; Mocellin, M; Rapoport, PB; Rosario, N; Solé, D; Wexler, L,
)
0.13
"rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects."( Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis.
Antila, M; Campos, RA; Castro, FM; Chavarria, ML; de Mello Junior, JF; de Mello, JF; Di Gesu, G; Guimarães, RE; Mion, Ode G; Mocellin, M; Rapoport, PB; Rosario, N; Solé, D; Wexler, L,
)
0.13
" Incidence of adverse effects was less in the rupatadine group compared with the levocetirizine group."( Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety.
Allala, U; Jaida, J; Maiti, R; Palani, A; Rahman, J, 2010
)
0.36
" The overall incidence of adverse drug reactions was also found to be less in rupatadine group."( Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety.
Ahmed, I; Goud, P; Jaida, J; Maiti, R; Palani, A; Raghavendra, BN, 2011
)
0.37
"Cyproheptadine is safe and effective for treating dyspeptic symptoms in children, particularly in young children and those with early vomiting and retching after fundoplication."( Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.
Diaz, J; Nurko, S; Rodriguez, L, 2013
)
2.14
"Cyproheptadine prevention of the neuropsychiatric adverse effects of an antiretroviral regimen including efavirenz has been evaluated in a randomized clinical trial."( Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
Akhondzadeh, S; Alimadadi, A; Dabaghzadeh, F; Ghaeli, P; Jafari, S; Khalili, H; Khazaeipour, Z, 2013
)
3.28
"In our experience, cyproheptadine appears to be safe and effective in decreasing vomiting and feeding intolerance in children less than three years of age."( A retrospective review of cyproheptadine for feeding intolerance in children less than three years of age: effects and side effects.
Butler, DR; Kaul, A; Meinzen-Derr, J; Merhar, SL; Mukkada, VA; Pentiuk, SP, 2016
)
1.06
"The review of these data indicates that rupatadine is highly selective for histamine H1-receptors, exhibits additional PAF antagonism in in vitro and in vivo studies, does not cross the blood-brain barrier, and has similar adverse events comparable with other second-generation antihistamines."( Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
Bachert, C; González-Núñez, V; Mullol, J, 2016
)
0.43
" The safety assessments showed that all treatment related side effects were of mild intensity and there were no serious adverse events (SAEs) or withdrawals due to treatment-emergent adverse events (TEAEs) in this study."( Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Ferber, G; Fernandes, S; Izquierdo, I; Lorch, U; Santamaría, E; Täubel, J, 2016
)
0.43
"This study demonstrated that rupatadine is safe and well tolerated by Japanese healthy subjects."( Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Ferber, G; Fernandes, S; Izquierdo, I; Lorch, U; Santamaría, E; Täubel, J, 2016
)
0.43
" No noteworthy dose-related increase in the incidence of adverse drug reactions was observed."( Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Aoki, H; Hide, M; Suzuki, T; Tanaka, A, 2019
)
0.51
" Adverse drug reactions (ADRs) were reported at an overall incidence of 18."( Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.
Aoki, H; Hide, M; Suzuki, T; Tanaka, A, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" Loratadine was rapidly absorbed and the decline of plasma concentrations after attainment of the Cmax was biexponential in all subjects."( Pharmacokinetics of loratadine in patients with renal insufficiency.
Halstenson, CE; Hilbert, J; Matzke, GR; Opsahl, JA; Perentesis, G; Radwanski, E; Zampaglione, N, 1990
)
0.28
"This article reviews clinical pharmacokinetic data on the H1-receptor antagonists, commonly referred to as the antihistamines."( Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines).
Paton, DM; Webster, DR,
)
0.13
" The plasma L and DCL concentration-time data in the disposition phases were fitted to a biexponential equation for pharmacokinetic analysis."( Loratadine: multiple-dose pharmacokinetics.
Hilbert, J; Radwanski, E; Symchowicz, S; Zampaglione, N, 1987
)
0.27
" Concentrations in the disposition phase were fitted to a biexponential equation for pharmacokinetic analysis."( Pharmacokinetics and dose proportionality of loratadine.
Hilbert, J; Luc, V; Perentesis, G; Radwanski, E; Symchowicz, S; Weglein, R; Zampaglione, N, 1987
)
0.27
" Concentrations of loratadine in the disposition phase were fitted to a biexponential equation and those of descarboethoxyloratadine to either a monoexponential or biexponential equation for pharmacokinetic analysis."( The pharmacokinetics of loratadine in normal geriatric volunteers.
Hilbert, J; Moritzen, V; Parks, A; Perentesis, G; Radwanski, E; Symchowicz, S; Zampaglione, N,
)
0.13
" The aim of this study was to further investigate these pharmacokinetic DMXAA-drug interactions in the rat model."( A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S, 2001
)
0.31
" The cause of the species difference in the pharmacokinetic response to thalidomide by DMXAA is unknown, and indicates difficulties in predicting the outcome of such a combination in patients."( A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S, 2001
)
0.31
" Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone."( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008
)
0.35
" The method has been successfully applied to a pharmacokinetic study of rupatadine and its major metabolite after oral administration of 10, 20 and 40mg rupatadine tablets to healthy Chinese volunteers."( Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: application to the pharmacokinetic study in healthy Chinese volunteers.
Fan, G; Hong, Z; Wei, H; Wen, J; Wu, Y, 2009
)
0.35
" The relationship between RUP plasma concentration, pharmacokinetic parameters, and polymorphic alleles (CYP3A5 and MDR1) were assessed."( CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Huang, S; Li, X; Liu, M; Xia, C; Xiong, Y; Yang, J; Yuan, Z; Zhang, H, 2016
)
0.43
" The method was successfully applied to a pharmacokinetic study of RT and its two metabolite DT and 3-OH-DT in healthy volunteers following single (10, 20, 40 mg) and multiple (10 mg) oral doses of rupatadine fumarate tablets."( Development of a highly sensitive LC-MS/MS method for simultaneous determination of rupatadine and its two active metabolites in human plasma: Application to a clinical pharmacokinetic study.
Ding, L; Gu, P; Li, Q; Liu, B; Pan, L; Sun, C; Wu, C; Zhang, J, 2015
)
0.42
"Exposure to rupatadine as measured by Cmax and AUC was found to increase in a dose dependent manner over the dose range of 10-40 mg for both single and multiple dose administration."( Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
Ferber, G; Fernandes, S; Izquierdo, I; Lorch, U; Santamaría, E; Täubel, J, 2016
)
0.43
"To optimise a pharmacokinetic (PK) study design of rupatadine for 2-5 year olds by using a population PK model developed with data from a study in 6-11 year olds."( Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.
Estévez, JA; Izquierdo, I; Riba, J; Santamaría, E; Valle, M, 2017
)
0.46
"5 mg, as it provided a Cmax below the 3 ng/ml threshold."( Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children.
Estévez, JA; Izquierdo, I; Riba, J; Santamaría, E; Valle, M, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of the benzodiazepines clonazepam (CLZ) and diazepam (DZ), introduced independently and in combination with cyproheptadine (CY) upon single and repeated application on apomorphine stereotypy in rats were studied."( Effects of single and repeated application of clonazepam and diazepam independently and in combination with cyproheptadine on apomorphine stereotypy in rats.
Georgiev, VP; Petkov, VV, 1984
)
0.69
" Susceptibility patterns of sensitive and resistant parasites were evaluated against calcium antagonists of several chemical classes (verapamil, cyproheptidine, desipramine and chlopromazine), alone and in combination with suramin, diminazene aceturate or melarsen oxide cyteamine."( Trypanocidal resistance in Trypanosoma evansi in vitro: effects of verapamil, cyproheptidine, desipramine and chlorpromazine alone and in combination with trypanocides.
Anene, BM; Anika, SM; Chukwu, CC; Ross, CA, 1996
)
0.29
"Present results showed that single oral doses of rupatadine 10 mg in combination with alcohol do not produce more cognitive and psychomotor impairment than alcohol alone."( Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
Antonijoan, R; Barbanoj, MJ; Donado, E; García-Gea, C; Izquierdo, I; Jané, F; Pérez, I; Solans, A, 2006
)
0.33
" Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone."( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008
)
0.35
" This study aimed to observe the effect of rupatadine fumarate combined with acupoint application in the treatment of allergic rhinitis complicated with diabetes and its effect on serum IgE levels."( Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes.
Chen, X; Jiang, P; Liu, Y; Shi, J; Zhang, W, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" It was established that as soon as the treatment with the anabolic drug peritol was completed, there appeared the morphological signs attesting to an increase in functional activity of vasculostromal elements of the small intestine, and the absorption rate of vitamin B12 got intensified."( [Effect of peritol on the functional and morphological characteristics of the small intestine in rats].
Bandurko, LN; Brodskiĭ, RA; Dedenkov, AN; Iavor, T; Khachirov, DG,
)
0.13
"The objective of this study was to compare in man the bioavailability of d-pseudoephedrine and azatadine from a repeat action tablet formulation and from conventional tablets."( Bioavailability of d-pseudoephedrine and azatadine from a repeat action tablet formulation.
Lim, J; Lin, C; Symchowicz, S, 1982
)
0.26
"Cyproheptadine appeared to be well tolerated in cats and had high bioavailability after oral administration."( Disposition of cyproheptadine in cats after intravenous or oral administration of a single dose.
Boothe, DM; Esparza, T; Gray, C; Norris, CR; Ragsdale, M, 1998
)
2.1
"The purpose of this study was to describe the effect of the concomitant intake of food on the pharmacokinetic profile and bioavailability of a single dose of rupatadine."( Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Carbó, ML; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2007
)
0.34
" The 90% CIs were included in the interval 80% to 125% for desloratadine and 3-hydroxydesloratadine, whereas 90% CI for rupatadine was shifted to the right of the interval used for comparing bioavailability of the drugs."( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008
)
0.35
" The significant interindividual differences of CYP3A5 and P-gp often cause bioavailability differences of some clinical drugs."( CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
Huang, S; Li, X; Liu, M; Xia, C; Xiong, Y; Yang, J; Yuan, Z; Zhang, H, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Cyproheptadine (CPH) and tipepidine (TP) were investigated. The disposition of CPH and its metabolites from plasma and the hepatic drug metabolizing enzyme activities in rats dosed singly or repeatedly was investigated.

ExcerptRelevanceReference
" However, this was not noted with the smaller dosage of HC 20-511."( Comparison of a new antihistamine HC 20-511 with cyproheptadine (Periactin) in chronic urticaria.
Kuokkanen, K, 1977
)
0.51
" The results showed that azatadine did not produce significant impairment of psychomotor function at either the standard 2 mg or the maximum recommended 4 mg per day dosage level."( Effects of azatadine maleate on subjective appraisal and psychomotor functions relevant to driving performance.
Biehl, B, 1979
)
0.26
" Intradermal histamine dose-response thresholds of pruritus were obtained before and after pretreatment with the three antihistamines and placebo in each subject."( Suppression of histamine-induced pruritus by three antihistaminic drugs.
Cohan, R; Leifer, KN; Rhoades, RB; Wittig, HJ, 1975
)
0.25
" The three diarrheal agents, administered intraperitoneally, showed dose-dependent and parallel dose-response curves with the following order of decreasing potency: PGF2 alpha, methacholine and 5-HTP."( Naloxone reversal of drug-induced diarrhea in mice.
Bertermann, RE; Dajani, EZ; Roge, EA; Schweingruber, FL; Woods, EM, 1979
)
0.26
"A total of twenty-nine patients have thus far been treated with deanol in various dosage levels for periods ranging from five to thirty days."( Deanol acetamidobenzoate (Deaner) in tardive dyskinesia.
Fann, WE; Stafford, JR, 1977
)
0.26
" The therapeutic cycles were standardized, for each drug, in the way of administration, dosage and total duration of the treatment."( [Therapeutic possibilities in idiopathic headaches. Analysis of about 1000 cases].
Agostoni, A; Brandi, G; Cottino, A; Gai, V; Gastaldi, L; Lisino, F; Nattero, G, 1976
)
0.26
" At the highest dosage tested, loratadine was less effective than phenobarbital as an inducer of 2B1 and 2B2, although the induction of these proteins could be detected immunochemically even at the lowest dosage of loratadine tested."( Evaluation of loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice.
Casciano, CN; Cayen, MN; Clement, RP; Parkinson, A, 1992
)
0.28
" Serum serotonin levels did not change after CRH stimulation in doses up to 3 micrograms/kg body weight), and cyproheptadine did not abolish the respiratory stimulation effect of hCRH in a dosage sufficient to suppress CRH."( Studies on facial temperature rise and involvement of serotonin in the respiratory stimulation by CRH.
Beyer, J; Brauer, A; Huber, I; Krause, U; Lehnert, H; Nink, M; Velten, A, 1991
)
0.49
"In order to elucidate the interaction between cyproheptadine (CPH) and tipepidine (TP), the disposition of CPH and its metabolites from plasma and the hepatic drug metabolizing enzyme activities in rats dosed singly or repeatedly were investigated."( Drug interaction between cyproheptadine and tipepidine. Effect of single and repeated administrations.
Fujii, Y; Iwaki, M; Ogiso, T; Tanino, T; Yamashita, K, 1991
)
0.84
" Further, astemizole has the longest time to relief of symptoms in this class; histamine wheal inhibition is not apparent until the second day of 10 mg dosing and does not peak for 9 to 12 days."( Pharmacology of antihistamines.
Woodward, JK, 1990
)
0.28
"Cyproheptadine-HCl raised the pain thresholds during hot plat test and writhing test in mice and tail flick test in rats, strengthened the hypnotic action by subthreshold dosage of sodium pentobarbital and chloral hydrate."( [Analgesic and antipyretic effects of cyproheptadine].
Cui, J; Fan, CK; Tan, JQ; Xu, B, 1990
)
1.99
" Neither dose of loratadine had any significant effect on the methacholine dose-response relationship."( Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma.
Holgate, ST; Town, GI, 1990
)
0.28
" Once-daily dosing is recommended."( Loratadine: a nonsedating antihistamine with once-daily dosing.
Barenholtz, HA; McLeod, DC, 1989
)
0.28
" Subsequent dose-response studies with other serotonergic and dopaminergic antagonists suggested that dopaminergic receptors are involved in the adaptive response to the irritant."( A role for dopamine as an endogenous protective factor in the rat stomach.
MacNaughton, WK; Wallace, JL, 1989
)
0.28
" It is concluded that 10 mg loratadine, administered once daily, controls the symptoms of rhinitis more effectively than 120 mg terfenadine given once daily in the last few hours of the 24 h dosing period."( Comparative efficacy of once daily loratadine versus terfenadine in the treatment of allergic rhinitis.
Banov, CH,
)
0.13
"9, respectively, indicating that there is little accumulation of either L or DCL after a multiple (once-a-day) dosage regimen."( Loratadine: multiple-dose pharmacokinetics.
Hilbert, J; Radwanski, E; Symchowicz, S; Zampaglione, N, 1987
)
0.27
"0 hour after dosing and the milk Cmax was 29."( Excretion of loratadine in human breast milk.
Affrime, MB; Hilbert, J; Perentesis, G; Radwanski, E; Symchowicz, S; Zampaglione, N, 1988
)
0.27
" One hour prior to dosing and 1, 2, 3, 4, 6, 8, 12, 16, 24, 28, 32, 36, 40, and 48 hours after dosing, histamine and saline were injected intradermally into opposite arms."( Effects of loratadine (SCH 29851) in suppression of histamine-induced skin wheals.
Dyer, JG; Gural, R; Kassem, N; Robillard, N; Roman, I, 1988
)
0.27
"01 to 1 microM were added to the incubation media, GH secretion was consistently inhibited and a dose-response relationship was observed between the cyproheptadine concentrations and the amounts of GH released into the media."( Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture.
Fukushima, T; Ishibashi, M; Yamaji, T, 1985
)
1.91
" Microspheres are injected into the carotid circulations and group embolus dose-response relationships are calculated."( A model for quantitative evaluation of embolic stroke therapy.
DeGirolami, U; Hemenway, CC; Henry, ME; Kochhar, A; Lyden, PD; Mazzarella, V; Zivin, JA, 1987
)
0.27
"beta cells in islets of Langerhans were studied in Sprague-Dawley rats dosed by gavage with 0 (control), 75, 150, 250 or 300 mg/kg body wt/day S-H 966 BS [1-(1-oxido-4-thiomorpholino)-3-(1-piperazinyl)], an isoquinoline derivative."( Cytoplasmic vacuolation of pancreatic beta cells of rats after oral administration of a derivative of isoquinoline.
Kast, A; Ueberberg, H, 1986
)
0.27
" The physiology of the anticholinergic system and physostigmine are discussed along with the indications, toxicity, and dosing of physostigmine."( Central anticholinergic syndrome in a child: a case report.
Richmond, M; Seger, D, 1985
)
0.27
" There was a significant dose-response effect of fenfluramine on Prl but not on GH levels."( Serotonergic regulation of prolactin and growth hormone secretion in man.
Lewis, DA; Sherman, BM, 1985
)
0.27
" In order to further study the mechanism of brain stimulation punishment, dose-response curves of two minor tranquilizers, chlordiazepoxide and pentobarbital, of two tryptamine antagonists, methysergide and cyproheptadine as well as of amphetamine on lever-pressing behavior of rats maintained by water reinforcement and punished by DPAG stimulation were determined."( Effect of minor tranquilizers, tryptamine antagonists and amphetamine on behavior punished by brain stimulation.
de Aguiar, JC; Graeff, FG; Morato de Carvalho, S, 1981
)
0.45
" Moreover, a dose-response relationship between TRH concentrations and ACTH secretion was observed."( Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.
Ishibashi, M; Yamaji, T, 1981
)
0.52
"6 Dose-response curves for the rate of drug-induced relaxation of tonic contractures produced in hypertonic 42."( The calcium antagonistic effects of cyproheptadine on contraction, membrane electrical events and calcium influx in the guinea-pig taenia coli.
Lowe, DA; Matthews, EK; Richardson, BP, 1981
)
0.54
" All drugs have been shown to inhibit specifically the locomotor activity potentiating effect of LSD in a low dosage range (0."( Effects of atypical antidepressants on LSD potentiated apomorphine hypermotility in rats.
Fink, H; Gold, R; Morgenstern, R, 1980
)
0.26
"1 The efficacy of the antihistamine azatadine maleate at maximum recommended dosage (4 mg/day) for 1 week was assessed relative to placebo in a double-blind crossover study of twenty patients with perennial allergic rhinitis."( Azatadine maleate in perennial allergic rhinitis: effects on clinical symptoms and choice reaction time.
Aman, MG; Hillas, JL; Somerfield, SD; Wilson, JD, 1980
)
0.26
" Eighty percent of patients had symptomatic relief with a twice daily dosage of 2 mg."( Azatadine maleate (Zadine): evaluation in the management of allergic rhinitis.
Hillas, JL; Somerfield, SD; Wilson, JD, 1981
)
0.26
" 6-OHDA produced a leftward shift of the dose-response curve of NA."( Comparative studies of the effects of 5-hydroxytryptamine and noradrenaline on the rat anococcygeus muscle.
Goyal, RK; Patel, NM; Verma, SC, 1981
)
0.26
"Cisplatin was administered at a dosage of 50 mg/m2 of body surface to 69 dogs with various neoplasms."( Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs.
Berg, J; Dennis, RA; L'Heureux, DA; Moore, AS; Rand, WM, 1994
)
0.58
" Remission was achieved with cyproheptadine up to a dosage of 24 mg/day."( Cyproheptadine treatment in Cushing's disease.
Alagöl, F; Azizlerli, H; Berker, F; Sandalci, O; Tanakol, R; Terzioğlu, T, 1996
)
2.03
" Dosing levels included various combinations of the two compounds, ranging from 0-16 ppm DON and 0-20 ppm CYP."( Effect of the appetite stimulant cyproheptadine on deoxynivalenol-induced reductions in feed consumption and weight gain in the mouse.
Prelusky, DB; Rotter, BA; Thompson, BK; Trenholm, HL, 1997
)
0.58
" A 12-hour dosing interval is acceptable, but an 8-hour interval may be indicated for some cats."( Disposition of cyproheptadine in cats after intravenous or oral administration of a single dose.
Boothe, DM; Esparza, T; Gray, C; Norris, CR; Ragsdale, M, 1998
)
0.65
" Cyproheptadine administration was adjusted to determine the lowest dosage that effectively maintained the cat's consistent use of the litter box."( Use of cyproheptadine to control urine spraying in a castrated male domestic cat.
Schwartz, S, 1999
)
1.67
" Inhibitory concentration (IC50) values for a number of compounds were calculated as means +/- SEM from dose-response determinations."( Second messengers in platelet aggregation evoked by serotonin and A23187, a calcium ionophore.
Cheema, M; Connor, JD; Gilani, AH; Rasheed, H; Rizvi, Z; Saeed, SA, 2001
)
0.31
"To investigate a dose-response relationship for paroxetine administration, and to determine whether a lower dose of paroxetine is sufficient to increase plasma ACTH and cortisol."( Paroxetine as a 5-HT neuroendocrine probe.
Inoue, N; Iwakawa, M; Kojima, H; Nakamura, J; Shiraishi, Y; Soeda, S; Son, Y; Soya, A; Terao, T; Ueda, N; Yoshimura, R, 2003
)
0.32
" Fifteen patients required dosing adjustments, 2 stopped treatment, and 7 changed to other agents for lack of efficacy."( Prophylactic treatment of pediatric migraine.
Diamond, S; Jones, V; Lewis, DW; Scott, D, 2004
)
0.32
"Youths with attention deficit hyperactivity disorder often experience weight loss on stimulants, which may limit optimal dosing and compliance."( A chart review of cyproheptadine for stimulant-induced weight loss.
Daviss, WB; Scott, J, 2004
)
0.66
" Rupatadine is a new second generation H(1)-antihistamine with once-daily dosing that may provide better control of symptoms than the currently used H(1)-receptor blockers because of its dual pharmacological profile (anti-PAF and anti-H(1))."( Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study.
Castillo, JA; De Molina, M; Guadaño, EM; Meseguer, J; Picado, C; Serra-Batlles, J; Valero, A, 2004
)
0.32
"A stability-indicating MEKC was developed and validated for the analysis of rupatadine in tablet dosage forms, using nimesulide as internal standard."( Determination of rupatadine in pharmaceutical formulations by a validated stability-indicating MEKC method.
da Silva Sangoi, M; da Silva, LM; Dalmora, SL; Nogueira, DR; Todeschini, V, 2008
)
0.35
" The simulated response after repeated once-daily administrations of 10 mg rupatadine showed a significant and maintained antihistaminic effect over time, between two consecutive dosing intervals."( Antihistaminic effects of rupatadine and PKPD modelling.
Carbo, ML; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A,
)
0.13
" Except for maximum observed concentration during a dosing interval (Cmax,ss) of 3-hydroxydesloratadine, on average, there were no statistically significant differences in mean plasma concentrations in any of the main pharmacokinetic parameters of rupatadine, desloratadine, and 3-hydroxydesloratadine when administered in combination with azithromycin or alone."( Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A, 2008
)
0.35
" The RINm5F cell insulin assay enabled the identification of aryl-aryl-amine DOR agonists that lacked an insulin-reducing effect and did not elevate blood glucose in repeated dosing studies conducted over a suprapharmacologic dose range."( Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine.
Baker, J; Brandt, MR; Bryant, S; Cai, C; Carson, JR; Chevalier, KM; Codd, EE; Colburn, RW; Coogan, TP; Dax, SL; Decorte, B; Flores, CM; Kemmerer, M; Legrand, EK; Lenhard, JM; Leone, AM; Lin, L; Mabus, JR; McDonnell, ME; McMillian, MK; McNally, JJ; Stone, DJ; Wang, CY; Zhang, SP, 2010
)
0.58
" Flares were induced before dosing and up to 96 h afterwards by intradermal PAF and histamine."( Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males.
Church, MK, 2010
)
0.36
" Time to death (survival time) was considered as the time period from dosage with Boophone disticha to time of death."( Pre-treatment of BALB/c mice with a centrally acting serotonin antagonist (cyproheptadine) reduces mortality from Boophone disticha poisoning.
Gadaga, LL; Mutseura, M; Tagwireyi, D, 2013
)
0.62
" Rupatadine has a rapid onset of action and a long-lasting effect, so a once-daily dosing is permitted, moreover is well tolerated by young adults and the elders."( Rupatadine for the treatment of urticaria.
Calogiuri, GF; Delle Donne, P; Di Leo, E; Ferrannini, A; Nettis, E; Vacca, A, 2013
)
0.39
" Analysed dosage forms contained cyproheptadine and dexamethasone in concentrations higher than therapeutic doses."( Determination of synthetic pharmaceutical adulterants in herbal weight gain supplements sold in herb shops, Tehran, Iran.
Akhgari, M; Bahmanabadi, L; Bazmi, E; Mousavi, Z; Saberi, N, 2018
)
0.76
" The adverse effects may limit optimal dosing and patients' compliance with treatment leading to the discontinuation of treatment."( Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial.
Elyasi, S; Kadkhoda Mezerji, F; Mohammadpour, AH; Moharreri, F, 2019
)
0.83
" The developed methods were applied to estimate rupatadine content in its pharmaceutical tablet dosage form with acceptable recoveries."( Resonance Rayleigh scattering and spectrofluorimetric approaches for the selective determination of rupatadine using erythrosin B as a probe: application to content uniformity test.
Abdel-Lateef, MA; Almahri, A; Derayea, SM; El Hamd, MA; Samir, E, 2021
)
0.62
" after treatment with CH were measured as well as dose-response relationship."( Cyproheptadine as an appetite stimulant in children with cystic fibrosis.
Farrow, N; Grunert, J; La Vanda, C; Tai, A; van der Haak, N, 2021
)
2.06
" No dose-response relationship was observed."( Cyproheptadine as an appetite stimulant in children with cystic fibrosis.
Farrow, N; Grunert, J; La Vanda, C; Tai, A; van der Haak, N, 2021
)
2.06
"We present the largest randomized, double-blind, placebo-controlled clinical trial of cyproheptadine versus placebo in healthy adults with poor appetite using the lowest effective dosage of cyproheptadine."( Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.
Cho, B; Cho, KH; Cho, YG; Kim, SY; Lee, JW; Park, YG; Yun, JM, 2021
)
1.14
"The goal of this study was to examine how the administration and dosing of the anti-serotonergic medication cyproheptadine hydrochloride (HCl) affects involuntary muscle hypertonicity of the spastic and paretic hands of stroke survivors."( Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke.
Bansal, N; Barry, A; Kamper, D; Roth, E; Seo, N; Stoykov, ME; Triandafilou, K; Vidakovic, L, 2022
)
1.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
antipruritic drugA drug, usually applied topically, that relieves pruritus (itching).
anti-allergic agentA drug used to treat allergic reactions.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
piperidines
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Cyproheptadine H1-Antihistamine Action87

Protein Targets (101)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID886
phosphopantetheinyl transferaseBacillus subtilisPotency64.07490.141337.9142100.0000AID1490; AID2701
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID493106
Fumarate hydrataseHomo sapiens (human)Potency24.90520.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency14.74030.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency28.23200.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.50160.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency25.47390.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency37.65050.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.00000.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency17.26530.001022.650876.6163AID1224838; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency3.70490.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency17.02890.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency13.06380.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.33320.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency13.33220.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency18.75230.000229.305416,493.5996AID1259244; AID743069; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency2.18760.00108.379861.1304AID1645840
polyproteinZika virusPotency24.90520.00308.794948.0869AID1347053
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency37.68580.035520.977089.1251AID504332
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency6.02460.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency6.36080.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID902
cytochrome P450 2C19 precursorHomo sapiens (human)Potency12.58930.00255.840031.6228AID899
D(1A) dopamine receptorHomo sapiens (human)Potency1.20310.02245.944922.3872AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency11.22020.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency15.87280.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency11.66810.00669.809418.4927AID1347050
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency26.12160.00378.618923.2809AID2668
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.81780.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.02700.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency8.17120.020010.786931.6228AID912
chaperonin GroELMethanococcus maripaludis S2Potency100.000031.622831.622831.6228AID488978
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency11.94200.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency18.83360.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency14.74030.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency5.30800.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency18.83360.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency11.94200.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency29.35920.009610.525035.4813AID1479145; AID1479148
Ataxin-2Homo sapiens (human)Potency19.95260.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium-dependent noradrenaline transporterMus musculus (house mouse)Ki0.29000.01200.09050.2900AID145696
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.00240.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.00130.00000.887110.0000AID625218
Prostaglandin G/H synthase 1Ovis aries (sheep)Ki0.00160.00162.12129.0000AID5444
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.56400.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.55900.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.03500.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.00800.00000.690210.0000AID141115; AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.01600.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.00310.00000.79519.1201AID141115; AID625154
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.00400.00010.579710.0000AID141115
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.00400.00011.48339.1400AID141115
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.00400.00010.68688.2600AID141115
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00040.629810.0000AID4791
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.00400.00010.66618.2600AID141115
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.00380.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.00340.00000.72926.9183AID141115; AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.28300.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.10600.00010.807410.0000AID625201
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.00400.00010.58908.2600AID141115
Glycogen phosphorylase, brain formHomo sapiens (human)Ki0.00400.00404.06807.0000AID141115
Glycogen phosphorylase, muscle formHomo sapiens (human)Ki0.00400.00403.43475.2000AID141115
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.01600.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.00400.00000.59729.1201AID141115; AID625151
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)17.04910.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki13.96790.00042.03378.6606AID625171
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.16400.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.08350.00000.651810.0000AID625253; AID63979
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.00310.00040.908610.0000AID4791
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00160.00010.601710.0000AID5514
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.03800.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.01700.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)1.27500.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.18500.00030.483410.0000AID625203
DRattus norvegicus (Norway rat)Ki0.06300.00010.610010.0000AID63015
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00010.25675.8000AID63015
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.12200.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.07000.00010.739610.0000AID625190
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.04600.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.00680.00000.54057.7600AID141115; AID625153
Endothelin receptor type BRattus norvegicus (Norway rat)Ki0.05010.00630.05750.3710AID6685
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.15800.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki0.07900.00010.836310.0000AID625252
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.56400.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.42450.00031.465610.0000AID145895; AID625207
Endothelin receptor type BHomo sapiens (human)Ki0.05010.00010.05430.3710AID6670; AID6685
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)0.19800.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki0.19500.00062.197310.0000AID625270
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.10700.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.05300.00000.360910.0000AID625200
D(1B) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00020.24622.0000AID63015
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.00100.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.00130.00000.385510.0000AID5355; AID5444; AID625192; AID697464
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.00240.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.00610.00010.954910.0000AID5945; AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.12200.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.07000.00031.29679.2440AID625190
D(4) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00020.18872.0000AID63015
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00040.615610.0000AID4791
Sodium-dependent serotonin transporterHomo sapiens (human)Ki4.10000.00000.70488.1930AID204880
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki0.05010.00000.14803.1800AID6670
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)Ki0.01100.00080.50322.8420AID5677
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.08800.00030.380610.0000AID1546005; AID6685
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.00370.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.00040.00000.511010.0000AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.04800.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.01600.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.00940.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.00600.00030.769310.0000AID625217
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.28100.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.13000.00020.522910.0000AID625221
D(2) dopamine receptorMus musculus (house mouse)Ki0.11200.11201.60643.9811AID61054
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.14000.00010.54948.4000AID61545
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.06300.00000.437510.0000AID63015
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)17.04910.00091.901410.0000AID625171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki13.96790.00211.840710.0000AID625171
Sodium-dependent serotonin transporterMus musculus (house mouse)Ki4.10000.00040.59574.1000AID204217
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)17.04910.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki13.96790.08582.95428.6606AID625171
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)IC50 (µMol)8.13330.00202.52666.0800AID1251558; AID1302504; AID1311948
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)Ki15.00000.00030.00030.0003AID1302523
TransporterRattus norvegicus (Norway rat)Ki0.29000.00010.866710.0000AID145696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorHomo sapiens (human)Kd5.40000.00010.40215.4000AID254254
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km106.00007.00007.00007.0000AID214939; AID624633
UDP-glucuronosyltransferase 1A3Homo sapiens (human)Km240.00007.34007.34007.3400AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (533)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen metabolic processGlycogen phosphorylase, muscle formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, muscle formHomo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEndothelin receptor type BHomo sapiens (human)
neural crest cell migrationEndothelin receptor type BHomo sapiens (human)
positive regulation of protein phosphorylationEndothelin receptor type BHomo sapiens (human)
renin secretion into blood streamEndothelin receptor type BHomo sapiens (human)
regulation of heart rateEndothelin receptor type BHomo sapiens (human)
regulation of pHEndothelin receptor type BHomo sapiens (human)
cell surface receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
negative regulation of adenylate cyclase activityEndothelin receptor type BHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin receptor type BHomo sapiens (human)
nervous system developmentEndothelin receptor type BHomo sapiens (human)
peripheral nervous system developmentEndothelin receptor type BHomo sapiens (human)
posterior midgut developmentEndothelin receptor type BHomo sapiens (human)
positive regulation of cell population proliferationEndothelin receptor type BHomo sapiens (human)
gene expressionEndothelin receptor type BHomo sapiens (human)
negative regulation of neuron maturationEndothelin receptor type BHomo sapiens (human)
response to organic cyclic compoundEndothelin receptor type BHomo sapiens (human)
vein smooth muscle contractionEndothelin receptor type BHomo sapiens (human)
calcium-mediated signalingEndothelin receptor type BHomo sapiens (human)
cGMP-mediated signalingEndothelin receptor type BHomo sapiens (human)
heparin metabolic processEndothelin receptor type BHomo sapiens (human)
melanocyte differentiationEndothelin receptor type BHomo sapiens (human)
regulation of fever generationEndothelin receptor type BHomo sapiens (human)
aldosterone metabolic processEndothelin receptor type BHomo sapiens (human)
enteric smooth muscle cell differentiationEndothelin receptor type BHomo sapiens (human)
positive regulation of urine volumeEndothelin receptor type BHomo sapiens (human)
renal sodium excretionEndothelin receptor type BHomo sapiens (human)
epithelial fluid transportEndothelin receptor type BHomo sapiens (human)
vasoconstrictionEndothelin receptor type BHomo sapiens (human)
vasodilationEndothelin receptor type BHomo sapiens (human)
negative regulation of apoptotic processEndothelin receptor type BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin receptor type BHomo sapiens (human)
macrophage chemotaxisEndothelin receptor type BHomo sapiens (human)
response to painEndothelin receptor type BHomo sapiens (human)
enteric nervous system developmentEndothelin receptor type BHomo sapiens (human)
regulation of epithelial cell proliferationEndothelin receptor type BHomo sapiens (human)
negative regulation of protein metabolic processEndothelin receptor type BHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of penile erectionEndothelin receptor type BHomo sapiens (human)
establishment of endothelial barrierEndothelin receptor type BHomo sapiens (human)
renal sodium ion absorptionEndothelin receptor type BHomo sapiens (human)
calcium ion transmembrane transportEndothelin receptor type BHomo sapiens (human)
cellular response to lipopolysaccharideEndothelin receptor type BHomo sapiens (human)
protein transmembrane transportEndothelin receptor type BHomo sapiens (human)
podocyte differentiationEndothelin receptor type BHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
renal albumin absorptionEndothelin receptor type BHomo sapiens (human)
neuroblast migrationEndothelin receptor type BHomo sapiens (human)
chordate pharynx developmentEndothelin receptor type BHomo sapiens (human)
response to sodium phosphateEndothelin receptor type BHomo sapiens (human)
response to endothelinEndothelin receptor type BHomo sapiens (human)
developmental pigmentationEndothelin receptor type BHomo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
bile acid secretionUDP-glucuronosyltransferase 1A3Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
DNA damage responseHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin remodelingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (122)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, brain formHomo sapiens (human)
nucleotide bindingGlycogen phosphorylase, muscle formHomo sapiens (human)
protein bindingGlycogen phosphorylase, muscle formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, muscle formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, muscle formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, muscle formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, muscle formHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
endothelin receptor activityEndothelin receptor type BHomo sapiens (human)
protein bindingEndothelin receptor type BHomo sapiens (human)
peptide hormone bindingEndothelin receptor type BHomo sapiens (human)
type 1 angiotensin receptor bindingEndothelin receptor type BHomo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3K4 monomethyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (87)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
extracellular regionGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
membraneGlycogen phosphorylase, brain formHomo sapiens (human)
azurophil granule lumenGlycogen phosphorylase, brain formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
cytosolGlycogen phosphorylase, muscle formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, muscle formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, muscle formHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
nuclear membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleolusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (238)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
AID1345908Human alpha1A-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID1345170Human 5-HT6 receptor (5-Hydroxytryptamine receptors)1996Journal of neurochemistry, Jan, Volume: 66, Issue:1
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
AID1346037Human H1 receptor (Histamine receptors)1994European journal of biochemistry, Sep-01, Volume: 224, Issue:2
Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene.
AID1345971Human alpha1D-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Sep-15, Volume: 90, Issue:18
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
AID1346000Human alpha1B-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Nov-05, Volume: 268, Issue:31
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1302514Inhibition of Set7/9 in human MCF7 cells assessed as reduction of ERalpha expression after 48 hrs by immunoblotting analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID49413Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 50/2561982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID1302509Inhibition of Set7/9 in human MCF7 cells assessed as suppression of beta-estradiol-induced cell viability incubated for 4 days by haemocytometer2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID49570Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 50/2211982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID1148116Orexigenic activity in cat assessed as food consumption at 0. 0312 mg/kg, po (Rvb = 133 +/- 31 g)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID254947Inhibitory concentration against LTD4-induced contraction of guinea pig ileum at 10 uM concentration2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID1132687Toxicity in adrenalectomized Sprague-Dawley rat at 10 mg/kg, iv1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID23962logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1302521Non competitive inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ac-KRSK-MCA peptide as substrate and varying SAM preincubated for 1 hr followed by substrate addition measured after 15 mins by Lineweaver-Bur2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1311949Displacement of [3H]ketanserin from Sprague-Dawley rat cerebral cortex 5-HT2A receptor after 30 mins by liquid scintillation counting analysis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.
AID49421Average food consumed at the dose of 0.50 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 47/1901982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID49401Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 35/2001982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID58619Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing for conversion to sinus rhythm.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID86244Inhibition of [3H]mepyramine binding with histamine H1 receptor in guinea pig cerebellum membranes after 30 min1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.
AID203926Serotonin antagonism in guinea pig 3 h after oral administration.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.
AID1132677Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID5355Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1148109Anticholinergic activity in po dosed CF-1 mouse assessed as dose required to increase pupil diameter to 1.5 micrometer after 1 hr1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID330659Effect on life span of Caenorhabditis elegans at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID330705Effect on life span of Caenorhabditis elegans ser7(tm1325) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID203927Serotonin antagonism in guinea pig 3 hr after subcutaneous administration.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1302526Inhibition of G9a (unknown origin) by fluorogenic assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26311logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID330703Effect on life span of Caenorhabditis elegans ser3(ok2007) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID356052Antiinflammatory activity against Naja mossambica PLA2-induced Swiss mouse paw edema assessed as inhibition of paw volume at 5 mg/kg, ip administered before 30 mins of PLA2 challenge measured after 30 mins relative to control2003Journal of natural products, Jun, Volume: 66, Issue:6
Warangalone, the isoflavonoid anti-inflammatory principle of Erythrina addisoniae stem bark.
AID1132678Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1251558Inhibition of SET7 (unknown origin)2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening.
AID1302504Inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using biotinylated histone H3-derived peptide/SAM as substrate by alphaLISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1148107Antiserotonin activity against po dosed Sprague-Dawley rat assessed as inhibition of serotonin-induced edema of right hind paw compound administered 1 hr prior to serotonin challenge1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID1302507Inhibition of Set7/9 in human MCF7 cells assessed as suppression of beta-estradiol-induced ERE promoter activation at 14 to 43 uM preincubated for 18 hrs followed by beta-estradiol addition measured after 24 hrs by luciferase reporter gene assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID63015Displacement of [3H]- spiperone radioligand binding at the dopamine binding site of rat caudate1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and receptor binding studies relevant to the neuroleptic activities of some 1-methyl-4-piperidylidene-9-substituted-pyrrolo[2,1-b][3]benzazepine derivatives.
AID1302518Inhibition of Set7/9 in human MCF7 cells assessed as ERalpha destabilization at 43 uM for 36 hrs by immunoblotting analysis in presence of proteasome inhibitor MG1322016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID63979Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID254254Dissociation constant against histamine H1 receptor2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID61054Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23966logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID178522Inhibition of histamine skin reaction in rat after 2 hr of oral administration.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID1311948Inhibition of recombinant SET7/9 (unknown origin) using biotinylated histone H3-derived peptide/SAM as substrate after 60 mins by AlphaLISA assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.
AID178529Inhibition of mydriatic activity in rat after 2 hr of oral administration.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID330724Effect on life span of Caenorhabditis elegans N2 treated on day 5 at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1332271Antiinflammatory activity in Wistar rat assessed as inhibition of dextran-induced paw edema administered orally 30 mins prior to dextran treatment measured after 3 hrs2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
In vivo and in silico anti-inflammatory mechanism of action of the semisynthetic (-)-cubebin derivatives (-)-hinokinin and (-)-O-benzylcubebin.
AID6685Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.
AID1302527Inhibition of Suv39h1 (unknown origin) by ELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID145895Binding affinity towards Norepinephrine transporter using [3H]nisoxitine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID5444Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID23968logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID49221Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 41/1601982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID49240Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 14/1121982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID330704Effect on life span of Caenorhabditis elegans ser4(ok512) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1302513Effect on body weight in Balb/c-nu/nu mouse xenografted with Fucci introduced human MCF7 cells at 20 mg/kg, ip qd administered as continuous dose for 8 days measured every 3 to 4 days until day 152016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID6670Binding affinity towards 5-hydroxytryptamine 7 receptor2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
First pharmacophoric hypothesis for 5-HT7 antagonism.
AID1132681Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis at 25 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID624633Drug glucuronidation reaction catalyzed by human recombinant UGT1A42005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1546005Displacement of [3H]5-HT from recombinant human 5-HT7 receptor expressed in African green monkey COS7 cells2019European journal of medicinal chemistry, Dec-01, Volume: 183Structure-activity relationships of serotonin 5-HT
AID76788In vivo histamine induced lethality after 24 hours of iv administration in guinea pig1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID1302523Inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ac-KRSK-MCA peptide/SAM as substrate preincubated for 1 hr followed by substrate addition measured after 15 mins by Dixon plot analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1132683Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production at 1 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1302511Antitumor activity against Fucci introduced human MCF7 cells xenografted in Balb/c-nu/nu mouse at 20 mg/kg, ip qd administered as continuous dose for 8 days measured every 3 to 4 days until day 152016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID5945Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID86241Potency against histamine H1 receptor on guinea pig ileum1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.
AID1132680Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2-induced anaphylaxis at 25 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID624632Drug glucuronidation reaction catalyzed by human recombinant UGT1A32005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID337405Antiinflammatory activity against PLA2-induced Swiss mouse paw edema at 5 mg/kg, ip administered 30 mins before PLA2 challenge2003Journal of natural products, Sep, Volume: 66, Issue:9
Griffonianone D, an isoflavone with anti-inflammatory activity from the root bark of Millettia griffoniana.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302528Inhibition of Set8 (unknown origin) by AlphaELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1279905 HTP (5-hydroxytryptophan) antagonism in mouse 0.5 hr after subcutaneous administration (0.003-0.1 dose range).1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties.
AID23960logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1302529Inhibition of Dot1L (unknown origin) by AlphaELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1148117Orexigenic activity in cat assessed as food consumption at 0. 25 mg/kg, po (Rvb = 179 +/- 31 g)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID76791In vivo histamine induced lethality after 8 hours of iv administration in guinea pig1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1302508Inhibition of Set7/9 in human MCF7 cells assessed as suppression of beta-estradiol-induced pS2 mRNA expression at 14 to 43 uM preincubated for 18 hrs followed by beta-estradiol addition measured after 24 hrs by RT-PCR analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302510Antitumor activity against Fucci introduced human MCF7 cells xenografted in Balb/c-nu/nu mouse at 20 mg/kg, ip qd administered as single dose2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID58617Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing 50% reduction in ectopic rate.. 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1302517Inhibition of Set7/9 in human MCF7 cells assessed as half life of ERalpha at 43 uM by immunoblotting analysis in presence of cycloheximide (Rvb = 15.6 +/- 1.2 hrs)2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID356053Antiinflammatory activity against Naja mossambica PLA2-induced Swiss mouse paw edema assessed as inhibition of paw volume at 5 mg/kg, ip administered before 30 mins of PLA2 challenge measured after 60 mins relative to control2003Journal of natural products, Jun, Volume: 66, Issue:6
Warangalone, the isoflavonoid anti-inflammatory principle of Erythrina addisoniae stem bark.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1132682Antiallergic activity in in rat stomach strips assessed as inhibition of PGE2alpha-induced anaphylaxis at 100 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID49237Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 59/1951982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID76789In vivo histamine induced lethality after 3 hours of iv administration in guinea pig1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID26310Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1302516Effect on ERalpha mRNA expression in human MCF7 cells at 4.3 to 43 uM after 48 hrs by RT-PCR analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1148108Antihistaminic activity against ip dosed Duncan-Harley guinea pig assessed as inhibition of histamine aerosol-induced bronchoconstriction compound administered 30 mins prior to histamine challenge1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
(+)- and (-)-3-Methoxycyproheptadine. A comparative evaluation of the antiserotonin, antihistaminic, anticholinergic, and orexigenic properties with cyproheptadine.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID61545Binding affinity at dopamine D2 receptor by [3H]spiperone displacement.1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors.
AID176160In vivo antihistaminic activity using compound 48/80 induced lethality test in rat after 2 hr( oral administration)1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID23976logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID49217Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 35/1181982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID330698Effect on life span of Caenorhabditis elegans eat2(ad1116) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1135534Peripheral anticholinergic activity in po dosed Carworth CF1 mouse assessed as dose required to produce pupil dilation to 1.5 micrometer units in 50% mouse after 2 hrs1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Synthesis and stereospecific antipsychotic activity of (-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine.
AID178534Inhibition of serotonin skin reaction in rat after 2 hr of oral administration.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-a mines.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID141115Displacement of [3H]- QNB binding at the muscarinic-cholinergic binding site of rat brain S11983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Synthesis and receptor binding studies relevant to the neuroleptic activities of some 1-methyl-4-piperidylidene-9-substituted-pyrrolo[2,1-b][3]benzazepine derivatives.
AID337406Antiinflammatory activity against PLA2-induced Swiss mouse paw edema at 5 mg/kg, ip administered 60 mins before PLA2 challenge2003Journal of natural products, Sep, Volume: 66, Issue:9
Griffonianone D, an isoflavone with anti-inflammatory activity from the root bark of Millettia griffoniana.
AID49213Average food consumed at the dose of 0.016 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 46/1931982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID330692Effect on life span of diet restricted Caenorhabditis elegans N2 at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID671883Inhibition of hypersensitive immune responses in rat passive cutaneous anaphylaxis model at 30 mg/kg2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302512Effect on body weight in Balb/c-nu/nu mouse xenografted with Fucci introduced human MCF7 cells at 20 mg/kg, ip qd administered as single dose2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID49394Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 30 min (control day/ test day); 34/1651982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID4791Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors.
AID145696Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID204217Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1135536Central anticholinergic activity against physostigmine-induced lethality in Carworth CF1 mouse assessed as animal death at 10 mg/kg, po treated 5 hrs before 1.6 mg/kg, sc physostigmine treatment and 2 mg/kg, ip atropine methyl nitrate treated 0.5 hrs befo1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Synthesis and stereospecific antipsychotic activity of (-)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine.
AID204880Binding affinity towards Serotonin transporter using [3H]paroxetine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID23972logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID49386Average food consumed at the dose of 0.25 mg/kg (po) using 10 cats per dose level at 180 min (control day/ test day); 45/2311982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID1302524Inhibition of G9a (unknown origin) by AlphaELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302522Competitive inhibition of recombinant Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using varying Ac-KRSK-MCA peptide as substrate in presence of SAM preincubated for 1 hr followed by substrate addition measured after 15 mins by Linewea2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID23975logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1132676Antiallergic activity in in guinea pig ileum strips assessed as inhibition of bradykinin-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1132686Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 3 mg/kg, iv after 30 mins by Evans blue staining1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID49246Average food consumed at the dose of 0.063 mg/kg (po) using 10 cats per dose level at 60 min (control day/ test day); 28/1301982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Synthesis and orexigenic activity of some 1-methyl-4-piperidylidene-Substituted pyrrolo[2,1-g][3] benzazepine and dibenzocycloheptene derivatives.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1302505Inhibition of recombinant his-tagged Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) using GST-fused histone H3 (1 to 57 residues) as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by Western blot analy2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302515Inhibition of Set7/9 in human MCF7 cells assessed as reduction of ERalpha expression at 43 uM by immunoblotting analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID1302525Inhibition of G9a (unknown origin) by ELISA2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID697464Antagonist activity at 5HT2A receptor2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
AID330691Effect on life span of Caenorhabditis elegans N2 treated on day 1 at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1576317Antiinflammatory activity in Swiss mouse assessed as reduction in dextran-induced paw edema at 10 mg/kg, po treated 1 hr prior to dextran challenge and measured every 60 mins for 4 hrs by plethysmometer analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Evaluation of anti-inflammatory activity and molecular docking study of new aza-bicyclic isoxazoline acylhydrazone derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID330660Effect on life span of Caenorhabditis elegans at 100 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132679Antiallergic activity in in guinea pig lung tissue assessed as inhibition of SRS-A production1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID23964logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1132688Antiallergic activity in in guinea pig ileum strips assessed as inhibition of histamine-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID23970logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1132675Antiallergic activity in in guinea pig ileum strips assessed as inhibition of serotonin-induced anaphylaxis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID5677Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID5514Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin receptor.
AID23973Partition coefficient (logD, measured by HPLC, log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID330696Effect on life span of Caenorhabditis elegans daf16(mu86) mutant at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132684Antiallergic activity in adrenalectomized Sprague-Dawley rat assessed as inhibition of egg albumin-induced passive cutaneous anaphylaxis reaction at 10 mg/kg, iv after 30 mins by Evans blue staining1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Antiallergic 9-oxo-11-hydroxy-5H,9H-[2]benzopyrano[4,3-g][1]benzopyrans.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,098)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901301 (62.01)18.7374
1990's376 (17.92)18.2507
2000's200 (9.53)29.6817
2010's167 (7.96)24.3611
2020's54 (2.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.24 (24.57)
Research Supply Index7.85 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index192.86 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (102.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials262 (11.41%)5.53%
Reviews119 (5.18%)6.00%
Case Studies218 (9.49%)4.05%
Observational3 (0.13%)0.25%
Other1,695 (73.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (23)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe A [NCT04108104]Phase 2154 participants (Actual)Interventional2019-11-30Completed
Effect of Cyproheptadine on Weight Gain and Feeding Behavior in 2 to 4 Years Old Children With Failure to Thrive [NCT01314989]Phase 420 participants (Anticipated)Interventional2010-12-31Recruiting
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients [NCT04488081]Phase 21,500 participants (Anticipated)Interventional2020-07-31Recruiting
Altering Activation Patterns in the Distal Upper Extremity After Stroke [NCT02418949]96 participants (Actual)Interventional2015-11-30Active, not recruiting
Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk [NCT01132547]Phase 322 participants (Actual)Interventional2010-06-30Terminated(stopped due to The study was terminated due to slow accrual.)
A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD [NCT01940978]Phase 499 participants (Actual)Interventional2014-03-31Completed
An Open Label Randomized Phase II Study of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children With Cancer/Treatment-Related Weight Loss [NCT00949117]Phase 29 participants (Actual)Interventional2009-09-30Terminated(stopped due to study not feasible with low accrual. DSMB recommended closure)
Mechanisms of Neuromuscular Fatigue Post Stroke [NCT01688570]Early Phase 127 participants (Actual)Interventional2011-08-31Completed
Molecular Markers of Neuroplasticity During High-Intensity Exercise in Subjects With Incomplete Spinal Cord Injury [NCT01538693]30 participants (Anticipated)Interventional2011-12-31Completed
A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking [NCT01076283]Phase 214 participants (Actual)Interventional2009-12-31Completed
Double-blind, Three-way Cross-over, Placebo-controlled Study to Assess the Efficacy, Safety and Mechanisms of Treatment With Rupatadine 20 mg and 40 mg in Cold Contact Urticaria (CCU) [NCT01605487]Phase 224 participants (Actual)Interventional2012-06-30Completed
The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia [NCT00066248]Phase 270 participants (Actual)Interventional2003-06-30Completed
Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders [NCT02568007]Phase 44 participants (Actual)Interventional2015-12-31Terminated(stopped due to Unable to enroll adequate participants)
The Pediatric Oncology Interventional Nutrition Therapy (POINT) Trial: A Pilot Study [NCT06175273]Phase 2/Phase 345 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial [NCT04820751]Phase 3200 participants (Anticipated)Interventional2021-04-10Not yet recruiting
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community With Fluvoxamine, Bromhexine, Cyproheptadine, and Niclosamide in Decreasing Recovery Time [NCT05087381]Phase 41,200 participants (Actual)Interventional2021-10-01Completed
Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19 [NCT04979221]Phase 3274 participants (Anticipated)Interventional2021-07-26Recruiting
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19: a Single-center, Observational Retrospective-prospective Comparative Study. [NCT04876573]Phase 260 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Noninvasive Markers of Functional Nausea in Children [NCT03593811]130 participants (Anticipated)Interventional2018-08-03Enrolling by invitation
A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine. [NCT02358265]Phase 3192 participants (Actual)Interventional2014-12-31Terminated(stopped due to poor recruitment)
Blocking the Effects of Serotonin to Prevent Ischemic Mitral Regurgitation: a Randomized Trial (CYPRO-MR) [NCT05469165]Phase 2214 participants (Anticipated)Interventional2023-06-20Recruiting
A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain [NCT01675050]Phase 24 participants (Actual)Interventional2012-08-31Terminated(stopped due to Due to the wide availability of the drug in clinical practice, it was impossible to recruit adequate numbers for scientific power.)
A Phase 1, Open-label, Cross-over Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Following Single Dose Oral Administration of KT110 Tablet and Following Administration of Alpress and Periactin Marketed Tab [NCT06147622]Phase 18 participants (Anticipated)Interventional2024-02-29Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00949117 (3) [back to overview]Body Mass Index as Assessed at Baseline and 24 Weeks
NCT00949117 (3) [back to overview]Change in Weight for Age Z-score From Baseline Through 24 Weeks
NCT00949117 (3) [back to overview]Difference Between Measures of Weight at Baseline and at Week 24
NCT01076283 (2) [back to overview]Alcohol Drinking
NCT01076283 (2) [back to overview]Alcohol Urge
NCT01132547 (3) [back to overview]Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline
NCT01132547 (3) [back to overview]Pattern of Weight in the Study Population
NCT01132547 (3) [back to overview]Severity of Weight Loss
NCT01675050 (2) [back to overview]Abdominal Pain
NCT01675050 (2) [back to overview]Pressure Pain Threshold
NCT02418949 (2) [back to overview]Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC)
NCT02418949 (2) [back to overview]Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT)

Body Mass Index as Assessed at Baseline and 24 Weeks

Change in Body Mass Index (BMI) in subjects from Baseline visit to 24 week visit. (NCT00949117)
Timeframe: 24 weeks

Interventionkg/m^2 (Mean)
Arm I- Cyproheptadine Hydrochloride1.9

[back to top]

Change in Weight for Age Z-score From Baseline Through 24 Weeks

Change in weight for age Z-score from Baseline through 24 weeks while on study treatment. Weight for age Z-score calculated using the Center for Disease Control and Prevention (CDC) weight-for-age Z score data tables. (NCT00949117)
Timeframe: Baseline and 24 weeks

Interventionz score (Mean)
Arm I- Cyproheptadine Hydrochloride1.47

[back to top]

Difference Between Measures of Weight at Baseline and at Week 24

Difference in measure of weight in kilograms of subject at baseline and at week 24 after continuing on study treatment for the entire 24 week period. (NCT00949117)
Timeframe: 24 weeks

Interventionkilograms (Mean)
Arm I- Cyproheptadine Hydrochloride4.3

[back to top]

Alcohol Drinking

"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionstandard drinking units (Mean)
Baclofen0.17
Cyproheptadine1.43

[back to top]

Alcohol Urge

"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration

Interventionunits on a scale (Mean)
Baclofen22.5
Cyproheptadine19.4

[back to top]

Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline

(NCT01132547)
Timeframe: 8 weeks

Interventionparticipants (Number)
Arm I Cyproheptadine Hydrochloride0
Arm II Placebo2

[back to top]

Pattern of Weight in the Study Population

Change from Baseline in Weight (NCT01132547)
Timeframe: Baseline and 8 weeks

InterventionKilograms (Mean)
Arm I Cyproheptadine Hydrochloride0.18
Arm II Placebo-0.32

[back to top]

Severity of Weight Loss

Change from Baseline in Weight Z score (NCT01132547)
Timeframe: Baseline and 8 weeks

InterventionZ score (Mean)
Arm I Cyproheptadine Hydrochloride0.12
Arm II Placebo-0.02

[back to top]

Abdominal Pain

"Participants rated the highest intensity of abdominal pain they experienced during the past two weeks on a scale of 0 (No Pain) to 10 (The Most Pain Possible), as derived from the Abdominal Pain Index - Child Version (Laird et al. 2015. Journal of Pediatric Psychology, 40(5), 517-525)." (NCT01675050)
Timeframe: 10 weeks

Interventionunits on a scale (Mean)
All Participants Post Cyproheptadine5.25
All Participants Post Placebo8

[back to top]

Pressure Pain Threshold

Increasing pressures were applied with a pressure plunger to the participants' thumbnail. The pressure at which the participant said that s/he felt pain is noted. The pressure is measured in kilograms by centimeters squared. (NCT01675050)
Timeframe: at 4 weeks of cyproheptadine or placebo treatment

Interventionkg/cm^2 (Mean)
All Participants Post Cyproheptadine1.15
All Participants Post Placebo1.23

[back to top]

Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC)

Following a maximum voluntary contraction (MVC) -- Time (s) required for muscle electromyographic (EMG) signals to reduce to within 3 SD of pre-MVC EMG activity. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)

InterventionSeconds (Mean)
Cyproheptadine + AMP-1.66
Placebo for Cyproheptadine + Stretching-0.96
Cyproheptadine + Stretching-1.06
Placebo for Cyproheptadine + AMP-2.65

[back to top]

Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT)

GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds. (NCT02418949)
Timeframe: baseline and 9 weeks (immediately post intervention)

InterventionSeconds (Mean)
Cyproheptadine + AMP-3.66
Placebo for Cyproheptadine + Stretching-0.51
Cyproheptadine + Stretching-4.00
Placebo for Cyproheptadine + AMP-3.89

[back to top]